Literature DB >> 26836899

Crises in Sickle Cell Disease.

Enrico M Novelli1, Mark T Gladwin2.   

Abstract

In spite of significant strides in the treatment of sickle cell disease (SCD), SCD crises are still responsible for high morbidity and early mortality. While most patients initially seek care in the acute setting for a seemingly uncomplicated pain episode (pain crisis or vaso-occlusive crisis), this initial event is the primary risk factor for potentially life-threatening complications. The pathophysiological basis of these illnesses is end-organ ischemia and infarction combined with the downstream effects of hemolysis that results from red blood cell sickling. These pathological changes can occur acutely and lead to a dramatic clinical presentation, but are frequently superimposed over a milieu of chronic vasculopathy, immune dysregulation, and decreased functional reserve. In the lungs, acute chest syndrome is a particularly ominous lung injury syndrome with a complex pathogenesis and potentially devastating sequelae, but all organ systems can be affected. It is, therefore, critical to understand the SCD patients' susceptibility to acute complications and their risk factors so that they can be recognized promptly and managed effectively. Blood transfusions remain the mainstay of therapy for all severe acute crises. Recommendations and indications for the safest and most efficient implementation of transfusion strategies in the critical care setting are therefore presented and discussed, together with their pitfalls and potential future therapeutic alternatives. In particular, the importance of extended phenotypic red blood cell matching cannot be overemphasized, due to the high prevalence of severe complications from red cell alloimmunization in SCD.
Copyright © 2016 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  acute chest syndrome; red blood cells; sickle cell disease; transfusion

Mesh:

Substances:

Year:  2015        PMID: 26836899      PMCID: PMC6637264          DOI: 10.1016/j.chest.2015.12.016

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  37 in total

Review 1.  Pathophysiology of Sickle Cell Disease.

Authors:  Prithu Sundd; Mark T Gladwin; Enrico M Novelli
Journal:  Annu Rev Pathol       Date:  2018-10-17       Impact factor: 23.472

2.  A locus on chromosome 5 shows African ancestry-limited association with alloimmunization in sickle cell disease.

Authors:  Lesedi M Williams; Zhihua Qi; Ken Batai; Stanley Hooker; Nancy J Hall; Roberto F Machado; Alice Chen; Sally Campbell-Lee; Yongtao Guan; Rick Kittles; Neil A Hanchard
Journal:  Blood Adv       Date:  2018-12-26

3.  Population Pharmacokinetics/Pharmacodynamics of Ticagrelor in Children with Sickle Cell Disease.

Authors:  Carl Amilon; Mohammad Niazi; Anders Berggren; Magnus Åstrand; Bengt Hamrén
Journal:  Clin Pharmacokinet       Date:  2019-10       Impact factor: 6.447

Review 4.  How we manage iron overload in sickle cell patients.

Authors:  Thomas D Coates; John C Wood
Journal:  Br J Haematol       Date:  2017-03-14       Impact factor: 6.998

5.  Vitamin D Deficiency and Its Association with Inflammatory Markers, Lipid Profile and Regulatory T-cells in Pediatric Sickle Cell Disease Patients.

Authors:  Yesim Oztas; Selma Unal; Gulcin Eskandari; Lulufer Tamer; Nuriman Ozgunes
Journal:  Indian J Hematol Blood Transfus       Date:  2017-10-13       Impact factor: 0.900

6.  Effectiveness and safety of oral anticoagulants in patients with sickle cell disease and venous thromboembolism: a retrospective cohort study.

Authors:  Megan Z Roberts; G Eric Gaskill; Julie Kanter-Washko; T Rogers Kyle; Brittany C Jones; Nicole M Bohm
Journal:  J Thromb Thrombolysis       Date:  2018-05       Impact factor: 2.300

7.  Featured Article: Depletion of HDL3 high density lipoprotein and altered functionality of HDL2 in blood from sickle cell patients.

Authors:  Eric Soupene; Sandra K Larkin; Frans A Kuypers
Journal:  Exp Biol Med (Maywood)       Date:  2017-04-24

8.  Association of Guideline-Adherent Antibiotic Treatment With Readmission of Children With Sickle Cell Disease Hospitalized With Acute Chest Syndrome.

Authors:  David G Bundy; Troy E Richardson; Matthew Hall; Jean L Raphael; David C Brousseau; Staci D Arnold; Ram V Kalpatthi; Angela M Ellison; Suzette O Oyeku; Samir S Shah
Journal:  JAMA Pediatr       Date:  2017-11-01       Impact factor: 16.193

Review 9.  Updated mechanisms underlying sickle cell disease-associated pain.

Authors:  Shibin Du; Corinna Lin; Yuan-Xiang Tao
Journal:  Neurosci Lett       Date:  2019-09-07       Impact factor: 3.046

10.  Low educational level of head of household, as a proxy for poverty, is associated with severe anaemia among children with sickle cell disease living in a low-resource setting: evidence from the SPRING trial.

Authors:  Halima Bello-Manga; Aisha A Galadanci; Shehu Abdullahi; Shehi Ali; Binta Jibir; Safiya Gambo; Lawal Haliru; Lori C Jordan; Muktar H Aliyu; Mark Rodeghier; Adetola A Kassim; Michael R DeBaun; Najibah A Galadanci
Journal:  Br J Haematol       Date:  2020-05-16       Impact factor: 6.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.